Table 3.
Comparison of symptomatic therapy and hospitalization data at onset between the PUs and PNUs
| Symptomatic therapy/hospitalization | Total patient cohort (n = 218) | Pediatrics units (n = 132) | Pediatric nephrology units (n = 86) | p value |
|---|---|---|---|---|
| Symptomatic therapy | ||||
| Albumin infusions | 119 (54.5) | 69 (52) | 50 (58) | 0.72 |
| Diuretics | 139 (63.7) | 82 (62.1) | 57 (66.2) | 0.13 |
| Vitamin D | 95 (43.6) | 51 (38.6) | 44 (51.2) | 0.068 |
| Proton pump inhibitors or H2 antagonists | 98 (44.9) | 49 (22.5) | 49 (57) | 0.016 |
| ASA | 47 (21.5) | 18 (13.6) | 29 (33.7) | <0.0001 |
| Calcium (carbonate or lactate) | 14 (6.4) | 9 (6.8) | 5 (5.8) | 0.34 |
| Ca channel blockers, ACE inhibitors | 9 (4.1) | 4 (3) | 5 (5.8) | 0.30 |
| Antibiotic prophylaxis | 34 (15.6) | 18 (13.6) | 16 (18.6) | 0.25 |
| Hospitalization data | ||||
| Hospitalization (days) | 10.7 (2–35) | 10.9 (2–35) | 10.4 (2–29) | 0.41 |
| Blood samples/days of hospitalization | 0.5 (0.1–1.5) | 0.49 (0.1–1.2) | 0.47 (0.1–1.5) | 0.70 |
Data are presented as the mean with the percentage in parenthesis, or as the median with the range in parenthesis
ASA, Acetylsalicylic acid; ACE angiotensin converting enzyme